companiesCompany

Exelixis

Exelixis makes cabozantinib (Cabometyx), used in kidney, liver, thyroid and, since 2025, neuroendocrine cancers.

Cabozantinib is approved in RCC (alone and with nivolumab), HCC after sorafenib (CELESTIAL), differentiated thyroid cancer, and advanced pancreatic and extra-pancreatic neuroendocrine tumours (CABINET, March 2025). Next-generation TKI zanzalintinib is in phase 3 in colorectal cancer and NETs.

Headquarters

Alameda, CA, US

Type

biotech · EXEL

Website

www.exelixis.com

Products

ApprovedSmall-molecule multi-kinase inhibitor (MET, VEGFR2, AXL, RET)

Cabozantinib · Cabometyx

A pill that blocks both blood-vessel growth and the MET escape pathway, used in kidney, liver, thyroid and, since 2025, neuroendocrine cancers.

Connected

Pages like this

not linked directly; found by shared links

Trial
CELESTIAL
Shares Cabozantinib, Hepatocellular carcinoma.
Trial
CABINET (Alliance A021602)
Shares Cabozantinib, Neuroendocrine tumours.
Trial
COSMIC-313
Shares Cabozantinib, Renal cell carcinoma.
Company
Eisai
Shares Thyroid cancer, Renal cell carcinoma, Hepatocellular carcinoma.
Trial
CONTACT-03
Shares Cabozantinib, Renal cell carcinoma.
Institution
Rutgers Cancer Institute of New Jersey
Shares Adrenocortical carcinoma, Neuroendocrine tumours.
Trial
CheckMate 9ER
Shares Cabozantinib, Renal cell carcinoma.
Idea
Kidney and liver impairment dosing studies completed before approval, not years after
Shares Renal cell carcinoma, Hepatocellular carcinoma.

cancers

6

Adrenocortical carcinoma Hepatocellular carcinoma Neuroendocrine tumours Osteosarcoma Renal cell carcinoma Thyroid cancer

fronts

1

Targeted Therapy

drugs

1

ApprovedSmall-molecule multi-kinase inhibitor (MET, VEGFR2, AXL, RET)

Cabozantinib · Cabometyx